Thymidine phosphorylase mRNA expression may be a predictor of response to post‑operative adjuvant chemotherapy with 
S‑1 in patients with stage III colorectal cancer

Ogawa,Masaichi; Watanabe,Michiaki; Mitsuyama,Yoshinobu; Anan,Tadashi; Ohkuma,Masahisa; Kobayashi,Tetsuya; Eto,Ken; Yanaga,Katsuhiko

doi:10.3892/ol.2014.2574

Thymidine phosphorylase mRNA expression may be a predictor of response to post‑operative adjuvant chemotherapy with S‑1 in patients with stage III colorectal cancer

Authors:
- Masaichi Ogawa
- Michiaki Watanabe
- Yoshinobu Mitsuyama
- Tadashi Anan
- Masahisa Ohkuma
- Tetsuya Kobayashi
- Ken Eto
- Katsuhiko Yanaga
View Affiliations

Affiliations: Department of Surgery, The Jikei University School of Medicine, Tokyo 105‑8461, Japan
Published online on: September 29, 2014 https://doi.org/10.3892/ol.2014.2574
Pages: 2463-2468

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate markers in surgically resected specimens of colorectal cancer that can be used to predict the response to chemotherapy. The mRNA expression levels of enzymes involved in 5‑fluorouracil (5‑FU) metabolism and folate metabolism were measured in formalin‑fixed, paraffin‑embedded tumor sections obtained from the primary tumors of 54 patients with resected stage II or III colorectal cancer who received S‑1 for one year. The 5‑FU metabolizing enzymes studied were thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase (TP). The folate metabolizing enzymes studied were folypolyglutamate synthetase, γ‑glutamyl hydrolase and dihydrofolate reductase. The associations between the mRNA expression levels of these enzymes and clinical variables were investigated. Tumors were classified as exhibiting high or low expression as compared with the median mRNA expression level of each metabolizing enzyme defined as the cutoff value. The associations between the high and low expression levels of each enzyme and disease‑free survival (DFS) were analyzed with the use of Kaplan‑Meier curves and the log‑rank test. DFS was not significantly associated with the relative mRNA expression level of any metabolizing enzyme in the study group as a whole, but there was a trend toward longer DFS in patients with high TP expression (P=0.066). In patients with stage III colorectal cancer, high TP expression was associated with significantly improved outcomes compared with low TP expression (P=0.039). These results indicate that the mRNA expression of TP, a metabolizing enzyme of 5‑FU, is a significant predictor of response to post‑operative chemotherapy with S‑1 in patients with stage III colorectal cancer.

View Figures

View References

1	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996.
2	Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park). 13(Suppl 3): 17–21. 1999.
3	Yamada Y, Hamaguchi T, Goto M, et al: Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer. 89:816–820. 2003.
4	Ohtsu A, Baba H, Sakata Y, et al: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 83:141–145. 2000.
5	Shirao K, Ohtsu A, Takada H, et al: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer. 100:2355–2361. 2004.
6	Muro K, Boku N, Shimada Y, et al: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860. 2010.
7	Sakuramoto S, Sasako M, Yamaguchi T, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
8	Sasako M, Sakuramoto S, Katai H, et al: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
9	Ogawa M, Watanabe M, Kobayashi T, et al: Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer. Int J Clin Oncol. 18:678–683. 2013.
10	Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.
11	Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 22:529–536. 2004.
12	Sobin LH and Wittekind Ch: TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, Inc; New York, NY: 2002
13	Bonner RF, Emmert-Buck M, Cole K, et al: Laser capture microdissection: molecular analysis of tissue. Science. 278:14811997.
14	Lord RV, Salonga D, Danenberg KD, et al: Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 4:135–142. 2000.
15	Satoh T and Sakata Y: S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother. 13:1943–1959. 2012.
16	Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53:4004–4009. 1993.
17	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996.
18	Mochizuki I, Takiuchi H, Ikejiri K, et al: Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer. 106:1268–1273. 2012.
19	Furukawa T, Yoshimura A, Sumizawa T, et al: Angiogenic factor. Nature. 356:6681992.
20	Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 88:1110–1117. 1996.
21	Nakayama Y, Inoue Y, Nagashima N, et al: Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res. 25:3755–3761. 2005.
22	Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 4:2371–2376. 1998.
23	Toi M, Hoshina S, Taniguchi T, et al: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 64:79–82. 1995.
24	Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human coborectal carcinoma. J Natl Cancer Inst. 88:1110–1117. 1996.
25	Maeda K, Chung YS, Ogawa Y, et al: Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer. 73:884–888. 1996.
26	Sadahiro S, Suzuki T, Tanaka A, Okada K, Nagase H and Uchida J: Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol. 70:285–291. 2012.
27	Hasegawa S, Seike K, Koda K, et al: Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol Rep. 13:621–626. 2005.
28	Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.
29	Yoshinare K, Kubota T, Watanabe M, et al: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci. 94:633–638. 2003.
30	Nishimura G, Terada I, Kobayashi T, et al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep. 9:479–482. 2002.
31	Jensen SA, Vainer B, Witton CJ, Jørgensen JT and Sørensen JB: Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncol. 47:1054–1061. 2008.
32	Collie-Duguid ES, Johnston SJ, Boyce L, et al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer. 94:297–301. 2001.